+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review

  • ID: 4282150
  • SWOT Analysis
  • July 2020
  • 56 pages
  • GlobalData

FEATURED COMPANIES

  • Aurobindo Pharma Ltd
  • Divi's Laboratories Ltd
  • Mylan Laboratories Ltd
  • Mylan NV
  • Pfizer Ltd
  • MORE
Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Glenmark Pharmaceuticals Ltd (Glenmark) focuses on the discovery and development of new chemical entities (NCEs). It develops and markets branded and generic formulations. The company's formulations business encompasses therapeutic areas such as dermatology, respiratory and oncology. It has also presence in other therapeutic areas such as diabetes, cardiovascular and oral contraceptives. It also offers a wide range of specialty and generic products. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark has manufacturing facilities in Argentina, the US, India and Czech Republic. The company markets its products in North America, Japan, Latin America, Europe, India, MENA, Asia and Russia, among others. Glenmark is headquartered in Mumbai, Maharashtra, India.

Glenmark Pharmaceuticals Ltd Key Recent Developments

Jun 26, 2020: Glenmark’s consolidated revenue rises 7.96% to Rs. 27,674.89 Mn. for Q4 FY 2019-20
Dec 16, 2019: Certificate Of compliance issued by The European Regulator, SUKL, Czech Republic for Glenmark'S Baddi manufacturing facility
Dec 16, 2019: State Institute for Drug control Inspects Glenmark’s Baddi Manufacturing Facility in India
Nov 14, 2019: Glenmark’s consolidated revenue rises 9.05% to Rs. 28,150.4 Mn. in Q2 FY 2019-20
Oct 05, 2019: Glenmark Pharmaceuticals: Update on the US FDA inspection of Glenmark’s Baddi manufacturing facility in Himachal Pradesh

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aurobindo Pharma Ltd
  • Divi's Laboratories Ltd
  • Mylan Laboratories Ltd
  • Mylan NV
  • Pfizer Ltd
  • MORE
Section 1 - About the Company
  • Glenmark Pharmaceuticals Ltd - Key Facts
  • Glenmark Pharmaceuticals Ltd - Key Employees
  • Glenmark Pharmaceuticals Ltd - Key Employee Biographies
  • Glenmark Pharmaceuticals Ltd - Major Products and Services
  • Glenmark Pharmaceuticals Ltd - History
  • Glenmark Pharmaceuticals Ltd - Company Statement
  • Glenmark Pharmaceuticals Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 – Company Analysis
  • Company Overview
  • Glenmark Pharmaceuticals Ltd - Business Description
  • Business Segment: API
  • Performance
  • Business Segment: Europe
  • Performance
  • Business Segment: India
  • Performance
  • Business Segment: Latin America
  • Performance
  • Business Segment: North America
  • Performance
  • Key Stats
  • Business Segment: Other Revenue
  • Performance
  • Business Segment: Rest of the World (ROW)
  • Performance
  • R&D Overview
  • Glenmark Pharmaceuticals Ltd - Corporate Strategy
  • Glenmark Pharmaceuticals Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Glenmark Pharmaceuticals Ltd - Strengths
  • Glenmark Pharmaceuticals Ltd - Weaknesses
  • Glenmark Pharmaceuticals Ltd - Opportunities
  • Glenmark Pharmaceuticals Ltd - Threats
  • Glenmark Pharmaceuticals Ltd - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • Jun 26, 2020: Glenmark’s consolidated revenue rises 7.96% to Rs. 27,674.89 Mn. for Q4 FY 2019-20
  • Dec 16, 2019: Certificate Of compliance issued by The European Regulator, SUKL, Czech Republic for Glenmark'S Baddi manufacturing facility
  • Dec 16, 2019: State Institute for Drug control Inspects Glenmark’s Baddi Manufacturing Facility in India
  • Nov 14, 2019: Glenmark’s consolidated revenue rises 9.05% to Rs. 28,150.4 Mn. in Q2 FY 2019-20
  • Oct 05, 2019: Glenmark Pharmaceuticals: Update on the US FDA inspection of Glenmark’s Baddi manufacturing facility in Himachal Pradesh
  • Oct 03, 2019: US FDA issues warning letter to Glenmark Pharmaceuticals
  • Aug 13, 2019: Glenmark’s consolidated revenue atRs.23,228.79 Mn.for Q1 FY 2019–20
  • May 07, 2019: Glenmark appoints Dr. Yasir Rawjee as chief executive officer of Glenmark Life Sciences, its subsidiary for the API business
  • Mar 28, 2019: Glenmark: Intimation of Appointment of Ms. Sona Saira Ramasastry as an Additional Director - independent Director
  • Mar 06, 2019: Glenmark Pharmaceuticals appoints Alessandro Riva as CEO of its new innovation company
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact
  • Disclaimer
List of Tables
  • Glenmark Pharmaceuticals Ltd, Key Facts
  • Glenmark Pharmaceuticals Ltd, Key Employees
  • Glenmark Pharmaceuticals Ltd, Key Employee Biographies
  • Glenmark Pharmaceuticals Ltd, Major Products and Services
  • Glenmark Pharmaceuticals Ltd, History
  • Glenmark Pharmaceuticals Ltd, Other Locations
  • Glenmark Pharmaceuticals Ltd, Subsidiaries
  • Glenmark Pharmaceuticals Ltd, Key Competitors
  • Glenmark Pharmaceuticals Ltd, Ratios based on current share price
  • Glenmark Pharmaceuticals Ltd, Annual Ratios
  • Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...1)
  • Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...2)
  • Glenmark Pharmaceuticals Ltd, Interim Ratios
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Glenmark Pharmaceuticals Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Glenmark Pharmaceuticals Ltd, Performance Chart (2016 - 2020)
  • Glenmark Pharmaceuticals Ltd, Ratio Charts
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Pfizer Ltd
  • Mylan NV
  • Mylan Laboratories Ltd
  • Emcure Pharmaceuticals Ltd
  • Dr. Reddy's Laboratories Ltd
  • Divi's Laboratories Ltd
  • Aurobindo Pharma Ltd
Note: Product cover images may vary from those shown
Adroll
adroll